Featured Research

from universities, journals, and other organizations

New approaches needed for treating chronic myeloid leukemia

Date:
December 13, 2010
Source:
Journal of Clinical Investigation
Summary:
The drug imatinib transformed chronic myeloid leukemia (CML) from a fatal disease to a chronic condition. However, imatinib must be taken lifelong, because it fails to kill a residual number of CML cells. New research, has now determined why these cells don't respond to imatinib -- they do not need the protein imatinib targets for their survival. Therefore, new approaches are needed if further advances are to be made in the care of CML patients.

The drug imatinib transformed chronic myeloid leukemia (CML) from a fatal disease to a chronic condition. However, imatinib must be taken lifelong, because it fails to kill a residual number of CML cells. New research, has now determined why these cells don't respond to imatinib -- they do not need the protein imatinib targets for their survival. Therefore, new approaches are needed if further advances are to be made in the care of CML patients.

Chronic myeloid leukemia (CML) was transformed from a fatal disease to a chronic condition by the development of a drug known as imatinib, which targets the protein that drives this disease (BCR-ABL).

However, imatinib does not cure patients, they must take the drug lifelong, as disease recurs if they stop taking it. This is because imatinib does not kill all the CML cells; some, which are known as CML stem cells, persist. A key to therapeutically targeting CML stem cells is knowing whether they rely on BCR-ABL to persist. Answers to this will determine whether more effective BCR-ABL inhibitors are likely to be effective treatments or whether new approaches to targeting these cells need to be developed.

A team of researchers, led by Brian Drucker and Michael Deininger, at Oregon Health and Science University, Portland, has now shown clearly that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. As noted by the authors and, in an accompany commentary, Alexander Perl and Martin Carroll, at the University of Pennsylvania, Philadelphia, the data indicate that therapeutics targeting BCR-ABL will not improve CML treatment and that new approaches are needed if further advances in patient care are to be made.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal References:

  1. Alexander Perl and Martin Carroll. BCR-ABL kinase is dead; long live the CML stem cell. Journal of Clinical Investigation, 2010 DOI: 10.1172/JCI43605
  2. Amie S. Corbin, Anupriya Agarwal, Marc Loriaux, Jorge Cortes, Michael W. Deininger and Brian J. Druker. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. Journal of Clinical Investigation, 2010 DOI: 10.1172/JCI35721

Cite This Page:

Journal of Clinical Investigation. "New approaches needed for treating chronic myeloid leukemia." ScienceDaily. ScienceDaily, 13 December 2010. <www.sciencedaily.com/releases/2010/12/101213121702.htm>.
Journal of Clinical Investigation. (2010, December 13). New approaches needed for treating chronic myeloid leukemia. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2010/12/101213121702.htm
Journal of Clinical Investigation. "New approaches needed for treating chronic myeloid leukemia." ScienceDaily. www.sciencedaily.com/releases/2010/12/101213121702.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins